araag2/HINT huggingface dataset:
Clinical trial NCT01429987 (phase 2/phase 3, status: completed)
Conditions: chronic idiopathic constipation
ICD codes: K59.04
Drugs: plecanatide
SMILES: [H][C@](C)(O)[C@]1([H])N=C(O)[C@]2([H])CSSC[C@]([H])(N=C(O)[C@]([H])(CCC(O)=O)N=C(O)[C@]([H])(CC(O)=O)N=C(O)[C@@]([H])(N)CC(O)=N)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CSSC[C@]([H])(N=C(O)CN=C1O)C(O)=N[C@@]([H])(CC(C)C)C(O)=O)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(C)C(O)=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged 18-75, inclusive

          -  Body Mass Index = 18-35 kg/m2, inclusive

          -  Meets modified Rome III criteria for functional chronic idiopathic constipation for at
             least 3 months with symptom onset for at least 6 months. Note: For this trial,
             patients with manual maneuvers required for >25% of defecations will not be eligible
             for participation.

          -  Less than 3 CSBMs per week at baseline and during pretreatment

          -  Completed a colonoscopy in accordance with medical guidelines as appropriate, with no
             clinically significant findings

          -  Patient is willing to discontinue use of supplemental fiber, laxatives, prescription
             and nonprescription medications, herbal or dietary supplements intended to treat
             constipation during the screening, pre-treatment, treatment and 2-week post-treatment
             periods

          -  Willing to maintain a stable diet during the study.

          -  Patients with hemorrhoids and/or diverticulosis (NOT diverticulitis) CAN be entered
             into the study.

        Exclusion Criteria:

          -  Loose stool (mushy) or watery (Bristol score- 6 or 7) stool in the absence of any
             laxative or prohibited medicine for > 25% of BMs during the 3 months prior to
             screening visit OR during the 14 day treatment period

          -  Patient meets the Rome III criteria for Irritable Bowel Syndrome (IBS-C)

          -  Active peptic ulcer disease not adequately treated or not stable

          -  History of cathartic colon, laxative, enema abuse, or ischemic colitis.

          -  Fecal impaction within 3 months of screening

          -  Patient has had /has any: diseases or conditions associated with constipation (GI or
             CNS), structural abnormality of the GI tract or gastric bypass surgery, pelvic floor
             dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal
             fissures or any disease or condition that can affect GI motility or defecation or can
             be associated with abdominal pain

          -  Unexplained and clinically significant "alarm symptoms" including lower GI bleeding,
             iron-deficiency anemia, weight loss or systemic signs of infection or colitis.

          -  Major surgery within 60 days of screening.
Clinical trial NCT01056380 (phase 2, status: terminated)
Conditions: influenza
ICD codes: J11.81, J11.82, J10.01, J10.81, J10.82, J11.08, J11.2
Drugs: nitazoxanide, placebo
SMILES: CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    insufficient enrollment during 2009-2010 flu season, new study initiated.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 to 65 years

          -  Fever, respiratory symptoms and constitutional symptoms compatible with influenza
             infection

          -  Influenza A or B infection in the local community

          -  Onset of illness no more than 48 hours before presentation

          -  Willing and able to provide comply with protocol requirements

        Exclusion Criteria:

          -  Severity of illness requiring or anticipated to require in-hospital care

          -  High risk of complications from influenza per IDSA (Infectious Diseases Society of
             America) guidelines or current CDC (Centers for Disease Control) criteria

          -  Females pregnant, breast-feeding or sexually active without birth control

          -  Vaccination for seasonal influenza or H1N1 on or after August 1, 2009

          -  Treatment with antiviral medication for influenza within 1 month prior to screening

          -  Treatment with nitazoxanide or any investigational drug within 1 month prior to
             screening

          -  Known sensitivity to nitazoxanide or any excipients

          -  Unable to take oral medications

          -  Chronic kidney or liver disease or known impaired hepatic and/or renal function

          -  Other pre-existing chronic infection undergoing or requiring medical therapy

          -  Pre-existing illness placing subject at unreasonably increased risk by participation
             in study

          -  Unlikely to comply with the requirements of this protocol
Clinical trial NCT00616655 (phase 2, status: completed)
Conditions: generalized anxiety disorder
ICD codes: F41.1
Drugs: eszopiclone, eszopiclone, placebo
SMILES: CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1, CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female subjects must be between 18 and 50 years of age

          -  Subjects must have GAD

          -  Subjects must be in otherwise good general health

        Exclusion Criteria:

          -  Subject has a documented history of HIV, hepatitis B or hepatitis C.

          -  Subject has a recent history (within 6 months of study entry) or current diagnosis of
             Major Depressive Disorder, panic disorder (or 3 or more panic attacks in the past
             month). Post Traumatic Stress Disorder, body dysmorphic disorder, eating disorder, or
             other disorder.

          -  Subject has a history or presence of Obsessive-Compulsive Disorder (OCD), any
             psychotic, bipolar or schizophrenic disorder.

          -  Subject has presence or history of antisocial personality or other severe disorder

          -  Subject has refractory GAD (previously unresponsive to 2 or more adequate courses of
             SSRI, SNRI, benzodiazepine or non-benzodiazepine treatment for GAD).

          -  Subject has history of seizures, including febrile seizures.

          -  Subject has initiated psychotherapeutic intervention with 30 days; however, continued
             psychotherapy is allowed if stable and not specifically directed at GAD.

          -  Subject is undergoing or has undergone electroconvulsive therapy.

          -  Subject is a current smoker or has smoked within the last 12 months.

          -  Subject has donated blood within the past 30 days or plans to donate during and within
             30 days after study participation.
Clinical trial NCT00544349 (phase 2, status: completed)
Conditions: colorectal cancer, metastatic cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: fluorouracil, leucovorin calcium, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary cancer of the colon or rectum

               -  Isolated hepatic metastases

               -  Not amenable to curative resection or requirement for complex and or larger
                  (i.e., > 4 liver segments) liver resection

          -  Measurable disease (RECIST criteria)

          -  Original tumor must be (or have been) removed

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  WHO performance status 0-1

          -  Life expectancy > 3 months

          -  ANC ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 9 g/dL

          -  Creatinine ≤ 1.5 times normal

          -  Bilirubin ≤ 1.5 times upper limit of normal

          -  Transaminases ≤ 5 times normal

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        Exclusion criteria:

          -  Contraindication or allergy grade 3-4 to any components of the study drugs

          -  Peripheral neuropathy

          -  Intestinal occlusion or subocclusion or prior inflammatory intestinal disease

          -  Severe cardiac disease including any of the following:

               -  Symptomatic coronary disease

               -  Myocardial infarction in the past 6 months

               -  New York Heart Association grade II-IV cardiac insufficiency

               -  Severe arrhythmia (even if treated)

          -  Active or uncontrolled infection

          -  Other concurrent serious disorder

          -  Severe uncontrolled medical condition

          -  Other malignancy within the past 5 years or concurrently except basal cell skin cancer
             or carcinoma in situ of the cervix

          -  Study impossible due to psychological, geographical, or social reasons

          -  Prisoners or patients under guardianship

        PRIOR CONCURRENT THERAPY:

        Exclusion criteria:

          -  Prior chemotherapy except adjuvant chemotherapy comprising fluorouracil, leucovorin
             calcium, capecitabine, oxaliplatin, irinotecan hydrochloride, and/or bevacizumab
             (completed > 6 months ago if oxaliplatin- or irinotecan-based)

          -  Prior epidermal growth factor (EGF), monoclonal antibody inhibiting transduction of
             EGF receptor (EGFR), or any other treatment targeting the EGFR

          -  Other concurrent anticancer immunotherapy, chemotherapy, or hormone therapy

          -  Participation in another study in the past 30 days
Clinical trial NCT00535366 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: tiotropium, salmeterol, fluticasone, ciclesonide low, ciclesonide high, placebo
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C, [H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Relatively stable, moderate to severe COPD

          -  Male or female patients 40 years of age or older.

          -  Current or ex-smokers with a smoking history of more than 10 pack years

        Exclusion Criteria:

          -  Other significant disease that can influence the study results or be a safety risk for
             the patient

          -  Other medication that can influence the study results

          -  Hypersensitivity to the study medication

          -  Patients with unstable COPD
Clinical trial NCT00142051 (phase 2, status: terminated)
Conditions: sickle cell disease
ICD codes: D57.1, D57.20, D57.212, D57.219, D57.211, D57.213, D57.218
Drugs: nitric oxide, oxygen
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O, O=O
Reason stopped: 
    18 or 20 enrolled, stopped due to paucity of available participants
  
Eligibility criteria:

        Inclusion Criteria:

          1. Hemoglobin SS, Hemoglobin Sß0thal or Hemoglobin SC documented by prior hemoglobin
             electrophoresis.

          2. Age 9 years or greater, age 22 years or less; pediatric age range, old enough to
             comply with mask and give reliable pain assessment score.

          3. Acute pain crisis defined as pain in abdomen, back and/or extremities that cannot be
             explained by a diagnosis other than sickle cell disease.

          4. Initial pain score at least 6 cm; to optimize the likelihood of observing a
             significant difference in change in pain score between INO treated and placebo groups.
             Based on data from our previous study, it is anticipated that patients will have an
             average pre-inhalation pain score of approximately 8 cm.

        Exclusion Criteria:

          1. > 24 pain crises in the last 12 months. Patients with very frequent pain crisis may
             have biologic and/or psychosocial pathophysiology that differs from those with fewer
             pain crises.

          2. Pain crisis treated at a medical facility within the last 12 hours.

          3. Use of investigational drugs other than hydroxyurea within the last 30 days.

          4. Significant respiratory compromise (initial SaO2 < 90%) and/or patients likely to have
             acute chest syndrome (chest pain and infiltrate) will be eliminated.

          5. Clinically significant acute or chronic cardiac dysfunction.

          6. Acute priapism.

          7. New focal neurologic symptoms.

          8. Concurrent documented or suspected bacterial or parvovirus infection.

          9. Temperature > 38.4ºC. These patients may have concomitant infection.

         10. Transfusion within 30 days or chronic transfusion therapy.

         11. Pregnant female

         12. Cigarette smoker > 1/2 ppd.

         13. Allergy to morphine

             -
Clinical trial NCT01359644 (phase 2, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: psi-7977, daclatasvir, ribavirin
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women, ages 18 to 70 years.

          -  Participants infected with hepatitis C virus (HCV) genotype 1, 2, or 3, with no
             previous exposure to an interferon formulation (ie, interferon-alpha, pegylated
             interferon-alpha) ribavirin, or other HCV-specific direct-acting antiviral (including
             daclatasvir and PSI-7977).

          -  Patients should have chronic hepatitis C genotype 1a, 1b, 2, or 3 as documented by:
             positive test results for anti-HCV antibody; HCV RNA; or a HCV genotype at least 6
             months prior to screening, and HCV RNA and anti-HCV antibody at the time of screening.

        Exclusion Criteria:

          -  Evidence of a medical condition associate with chronic liver disease other than HCV.

          -  History of variceal bleeding, hepatic encephalopathy, or ascites requiring management
             with diuretics or paracentesis.

          -  History of hemophilia.

          -  History of torsade de pointes.

          -  Current or known history of cancer (except in situ carcinoma of the cervix or
             adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior
             to enrollment.

          -  History of gastrointestinal disease or surgical procedure (except cholecystectomy).

          -  History of clinically significant cardiac disease.

          -  Blood transfusion within 4 weeks prior to study drug administration.

          -  Poor venous access.

          -  Any other medical, psychiatric, and/or social reason which, in the opinion of the
             Investigator, would make the candidate inappropriate for participation in this study.
Clinical trial NCT00553800 (phase 2, status: unknown status)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: bevacizumab, erlotinib
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Cytologically or histologic confirmed non-small cell lung cancer, stage IIIB or IV or
             recurrent after primary surgery or radiotherapy.

          -  ECOG PS 0-1

          -  70 years of age or older

          -  Must have measurable disease

          -  ANC > 1500, platelets > 100,000

          -  Total bilirubin </= 1.5, SGOT * SGPT < 5 x ULN

          -  Able and willing to swallow and absorb oral medication

          -  Able and willing to sign consent

          -  Request archival diagnostic tissue for EGFR expression but not required

        Exclusion Criteria:

          -  Proteinuria as demonstrated by UPC ratio >/= 1.0

          -  Prior treatment with an investigational or marketed inhibitor of the EGFR pathway or
             anti-angiogenesis agent (includes thalidomide)

          -  Prior treatment for advanced stage disease, with the exception of surgery or radiation
             (no systemic)

          -  History of gross hemoptysis within 1 month of enrollment unless treated with surgery
             or radiation

          -  Evidence of bleeding diathesis or coagulopathy or other serious/acute internal
             bleeding within 6 months of enrollment.

          -  Current, ongoing treatment with full dose warfarin or equivalent

          -  Current(within 10 days)use of aspirin (> 325mg/day) or other NSAID with antiplatelet
             activity

          -  History of hemorrhagic or thrombotic stoke, TIA, or other CNS bleeding w/in last 6
             months. Clinically significant PVD

          -  Known CNS disease except for treated brain mets.

          -  Squamous cell histology

          -  Blood pressure > 150/100 that cannot be ameliorated with standard anti-hypertensives

          -  History of hypertensive crisis or hypertensive encephalopathy

          -  NYHA grade II or > CHF

          -  History of MI within 6 months of enrollment

          -  Major surgery, open biopsy, significant trauma within 28 days of enrollment

          -  Pregnancy, lactation

          -  Abdominal or other fistula, abcess, perforation
Clinical trial NCT01096862 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: peficitinib, placebo
SMILES: NC(=O)C1=CN=C2NC=CC2=C1N[C@H]1[C@H]2CC3C[C@@H]1C[C@@](O)(C3)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has moderate to severe plaque psoriasis for 6 months or longer with at least
             10% Body Surface Area (BSA) affected

          -  Subject must be a candidate for phototherapy and/or systemic therapy

        Exclusion Criteria:

          -  Subject has non-plaque psoriasis or drug-induced psoriasis

          -  Subject is on systemic psoriasis therapy within 56 days or 5 half-lives, whichever is
             longer, prior to first dose of study drug

          -  Subject has a positive TB skin test within 3 months of screening or at screening

          -  Subject has an abnormal chest x-ray
Clinical trial NCT01179737 (phase 2, status: terminated)
Conditions: pulmonary arterial hypertension
ICD codes: I27.21
Drugs: nilotinib, placebo to nilotinib
SMILES: CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F, CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F
Reason stopped: 
    study was terminated due to serious adverse event (sae)
  
Eligibility criteria:

        Inclusion Criteria:

          -  World Health Organization (WHO) Functional Class II or III

          -  6MWD ≥ 150 m and ≤ 450 m at screening

          -  Current diagnosis of PAH according to Dana Point 2008 Meeting

          -  Inadequate clinical response on one or more class(es) of PAH drug

          -  Stabilization of pulmonary hypertension medications for ≥ 2 months on approved
             therapeutic dose of at least one PAH drug and still symptomatic with WHO functional
             Class II or III performance.

        Exclusion Criteria:

          -  Women of child-bearing potential not practicing birth control

          -  In treatment with chronic nitric oxide therapy

          -  Pre-existing lung disease

          -  Use of drugs prolonging the QT interval or strong CYP3A4 inhibitors

          -  Long QT syndrome or QTc > 450 ms males; > 470 ms females.

          -  WHO Class IV

          -  Pulmonary capillary wedge pressure > 15 mm Hg

          -  Other diagnosis of PAH in WHO Diagnostic Group 1

          -  PAH associated with: venous hypertension (WHO Diagnostic Group II), hypoxia (WHO
             Diagnostic Group III), chronic pulmonary thromboembolic disease (WHO Diagnostic Group
             IV) or other miscellaneous causes (WHO Diagnostic Class V, which includes sarcoidosis,
             histiocytosis X, lymphangiomatosis, compression of pulmonary vessels)

          -  Thrombocytopenia < 50 x109/L (50 x 103/µL)

          -  Uncontrolled systemic arterial hypertension, systolic > 160 mm Hg or diastolic >90 mm
             Hg

          -  Any advanced, severe, or unstable disease of any type that may interfere with the
             primary and secondary endpoint evaluations.

        Other protocol-defined inclusion/exclusion criteria may apply